Tactics and technologies to manage nonadherence in patients with schizophrenia

Current Psychiatry Reports

Volumn 10, Issue 4, 2008, Pages 359-369

  Glazer, William M ^a   Byerly, Mathew J ^b  

^a Glazer Medical Solutions   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; COGNITIVE THERAPY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE DELIVERY; HUMAN; LONG TERM CARE; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREATMENT PLANNING; UNITED STATES;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 48749088556     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-008-0057-7     Document Type: Review

References (93)

1. Herz MI, Glazer W, Mirza M, et al.: Treating prodromal episodes to prevent relapse in schizophrenia. Br J Psychiatry 1989, 155(Suppl 5):123-127.
2. Spaniel F, Vohlidka P, Hrdlicka J, et al.: ITAREPS: Information Technology Aided Relapse Prevention Programme in Schizophrenia. Schizophr Res 2008, 98:312-317.
3. Byerly MJ, Thompson A, Carmody T, et al.: Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007, 58:844-847.
4. Lacro JP, Dunn LB, Dolder CR, et al.: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
5. Cooper D, Moisan J, Gregoire JP: Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007, 68:818-825.
6. Law MR, Sournerai SB, Ross-Degnan DR, Adams AS: A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69:47-53.
7. Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55:886-891.
8. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429.
9. Gilmer TP, Dolder CR, Lacro JP, et al.: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699.
10. Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23:2305-2312.
11. Kane JM: Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006, 67(Suppl 5):9-14.
12. Velligan DI, Wang M, Diamond P, et al.: Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007, 58:1187-1192.
13. Ascher-Svanum H, Zhu B, Faries D, et al.: A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 2006, 67:1114-1123.
14. Velligan DI, Lam YW, Glahn DC, et al.: Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006, 32:724-742.
15. Byerly M, Fisher R, Whatley K, et al.: A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005, 133:129-133.
16. McClellan TA, Cowan G: Use of antipsychotic and antidepressant drugs by chronically ill patients. Am J Psychiatry 1970, 126:1771-1773.
17. Valenstein M, Barry KL, Blow FC, et al.: Agreement between seriously mentally ill veterans and their clinicians about medication compliance. Psychiatr Serv 1998, 49:1043-1048.
18. Woltmann EM, Valenstein M, Welsh DE, et al.: Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv 2007, 58:864-867.
19. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007, 298:61-69.
20. Pomykacz B, Mao M, Weiss RD, Teter CJ: A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder. Harv Rev Psychiatry 2007, 15:259-263.
21. Byerly MJ, Nakonezny PA, Rush AJ: The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 2008, 100:60-69.
22. Diaz E, Levine HB, Sullivan MC, et al.: Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci 2001, 26:325-329.
23. Nakonezny PA, Byerly MJ, Rush AJ: Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res 2008, 157:259-263.
24. Remington G, Kwon J, Collins A, et al.: The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007, 90:229-237.
25. Steiner JF, Koepsell TD, Fihn SD, Inui TS: A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988, 26:814-823.
26. Dolder CR, Lacro JP, Dunn LB, Jeste DV: Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002, 159:103-108.
27. Valenstein M, Copeland LA, Blow FC, et al.: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639.
28. Eaddy M, Grogg A, Locklear J: Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005, 27:263-272.
29. Frazier RS, Casper ES: A comparative study of clinical events as triggers for psychiatric readmission of multiple recidivists. Psychiatr Serv 1998, 49:1423-1425.
30. Marder SR: Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998, 59(Suppl 3):21-25.
31. Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
32. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
33. Rosenheck R, Chang S, Choe Y, et al.: Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000, 61:382-386.
34. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH: Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006, 144:177-189.
35. Al-Zakwani IS, Barron JJ, Bullano MF, et al.: Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003, 19:619-626.
36. Becker MA, Young MS, Ochshorn E, Diamond RJ: The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health 2007, 34:307-314.
37. Vanelli M, Burstein P, Cramer J: Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv 2001, 52:1248-1250.
38. Grunebaum MF, Weiden PJ, Olfson M: Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry 2001, 62:394-399.
39. Olfson M, Mechanic D, Hartsell S, et al.: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000, 51:216-222.
40. Cabeza IG, Amador MS, Lopez CA, Gonzalez de Chavez M: Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000, 41:349-355.
41. Menzin J, Boulanger L, Friedman M, et al.: Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003, 54:719-723.
42. Diaz E, Neuse E, Sullivan MC, et al.: Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004, 65:354-360.
43. Nakonezny PA, Byerly MJ: Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res 2006, 82:107-114.
44. Perkins DO, Johnson JL, Hamer RM, et al.: Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006, 83:53-63.
45. Hogarty GE, Schooler NR, Ulrich R, et al.: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979, 36:1283-1294.
46. Buchanan A: A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992, 22:787-797.
47. Weiden P, Rapkin B, Zygmunt A, et al.: Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995, 46:1049-1054.
48. Nageotte C, Sullivan G, Duan N, Camp PL: Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997, 32:49-56.
49. Garavan J, Browne S, Gervin M, et al.: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998, 39:215-219.
50. Keith SJ, Kane JM: Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003, 64:1308-1315.
51. Chue P, Emsley R: Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007, 21:441-448.
52. Schatzberg AF, Cole JO, Debattista C: Manual of Clinical Psychopharmacology, edn 6. Washington, DC: American Psychiatric Publishing; 2007.
53. Glazer WM, Kane JM: Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992, 53:426-433.
54. Glazer WM: Who receives long-acting antipsychotic medications? Psychiatr Serv 2007, 58:437.
55. Glazer WM: The depot paradox. Behav Healthc 2007, 27:44-46.
56. Eisenthal S, Emery R, Lazare A, Udin H: "Adherence" and the negotiated approach to patienthood. Arch Gen Psychiatry 1979, 36:393-398.
57. National Council on Patient Information and Education: Children and America's Other Drug Problem: Guidelines for Improving Prescription Medicine Use Among Children and Teenagers. Bethesda, MD: National Council on Patient Information and Education; 1989.
58. National Institute of Mental Health: Research on Adherence to Interventions for Mental Disorders. Bethesda, MD: National Institute of Mental Health; 1999. [NIMH publication no. PA-00-016.]
59. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005, 353:487-497.
60. Moore TA, Covell NH, Essock SM, Miller AL: Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007, 30:401-416.
61. Weiden PJ, Rao N: Teaching medication compliance to psychiatric residents: placing an orphan topic into a training curriculum. Acad Psychiatry 2005, 29:203-210.
62. Byerly MJ, Nakonezny PA, Lescouflair E: Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007, 30:437-452.
63. Corrigan PW, Liberman RP, Engel JD: From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990, 41:1203-1211.
64. Perkins DO: Adherence to antipsychotic medications. J Clin Psychiatry 1999, 60(Suppl 21):25-30.
65. Heinssen RK: Improving medication compliance of a patient with schizophrenia through collaborative behavioral therapy. Psychiatr Serv 2002, 53:255-257.
66. Noordsy DL, Torrey WC, Mead S, et al.: Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. J Clin Psychiatry 2000, 61(Suppl 3):22-29.
67. Engel GL: The clinical application of the biopsychosocial model. Am J Psychiatry 1980, 137:535-544.
68. Zygmunt A, Olfson M, Boyer CA, Mechanic D: Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002, 159:1653-1664.
69. Dolder CR, Lacro JP, Leckband S, Jeste DV: Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003, 23:389-399.
70. Gray R, Wykes T, Gournay K: From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. J Psychiatr Ment Health Nurs 2002, 9:277-284.
71. Lincoln TM, Wilhelm K, Nestoriuc Y: Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res 2007, 96:232-245.
72. Nose M, Barbui C, Gray R, Tansella M: Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003, 183:197-206.
73. Regier DA, Farmer ME, Rae DS, et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
74. Hunt GE, Bergen J, Bashir M: Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002, 54:253-264.
75. Bellack AS, DiClemente CC: Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999, 50:75-80.
76. Wilk J, Marcus SC, West J, et al.: Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis 2006, 194:454-457.
77. Ho AP, Tsuang JW, Liberman RP, et al.: Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry 1999, 156:1765-1770.
78. Barrowclough C, Haddock G, Tarrier N, et al.: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001, 158:1706-1713.
79. Haddock G, Barrowclough C, Tarrier N, et al.: Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 2003, 183:418-426.
80. Bellack AS, Bennett ME, Gearon JS, et al.: A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006, 63:426-432.
81. Kemp R, Hayward P, Applewhaite G, et al.: Compliance therapy in psychotic patients: randomized controlled trial. BMJ 1996, 312:345-349.
82. Kemp R, Kirov G, Everitt B, et al.: Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998, 172:413-419.
83. O'Donnell C, Donohoe G, Sharkey L, et al.: Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003, 327:834.
84. McIntosh AM, Conlon L, Lawrie SM, Stanfield AC: Compliance therapy for schizophrenia. Cochrane Database Syst Rev 2006, 3:CD003442.
85. Gray R, Leese M, Bindman J, et al.: Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial. Br J Psychiatry 2006, 189:508-514.
86. Byerly MJ, Fisher R, Carmody T, Rush AJ: A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005, 66:997-1001.
87. Velligan DI, Mueller J, Wang M, et al.: Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006, 57:219-224.
88. Velligan DI, Diamond PM, Mintz J, et al.: The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 2008, 34:483-493.
89. Pitschel-Walz G, Bauml J, Bender W, et al.: Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. J Clin Psychiatry 2006, 67:443-452.
90. Claassen D: Financial incentives for antipsychotic depot medication: ethical issues. J Med Ethics 2007, 33:189-193.
91. Glazer WM: What are "best practices"? Understanding the concept. Hosp Community Psychiatry 1994, 45:1067-1068.
92. Heyscue BE, Levin GM, Merrick JP: Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998, 49:1232-1234.
93. Velligan DI, Bow-Thomas CC, Huntzinger C, et al.: Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000, 157:1317-1323.